

**George N. Dalekos, MD, PhD**

**PROFESSOR OF MEDICINE  
HEAD OF THE DEPARTMENT OF  
MEDICINE AND THE RESEARCH  
LABORATORY OF INTERNAL MEDICINE  
UNIVERSITY OF THESSALY  
FACULTY OF HEALTH SCIENCES  
MEDICAL SCHOOL  
LARISSA, GREECE**

**CURRICULUM VITAE  
(Brief Edition)**

**LARISSA, April 2013**

## Curriculum Vitae

**First name:** George  
**Family's name:** Dalekos  
**Father's name:** Nikolaos  
**Mother's name:** Eymorphia  
**Place of birth:** Athens, Greece  
**Date of birth:** November 23, 1960  
**Citizenship:** Greek  
**Profession:** Professor of Medicine, Head, Department of Medicine and the Research Laboratory of Internal Medicine, University of Thessaly, Medical School.  
**Marital Status:** Married, father of two children  
**Home address:** M. Dorotheou 1b, 41447 Larissa, Greece  
**Office address:** University of Thessaly, Faculty of Health Sciences, Medical School, Biopolis, 41110 Larissa, Greece  
**Telephone:** 0030-241350-2285 (secretary)/ 0030-2410-685726  
**Fax:** 0030-241350-1557  
**e-mail** dalekos@med.uth.gr  
**Languages:** Greek, English

### Education

1985 MD, Athens Medical School, University of Athens, Greece  
 1995 Doctoral Thesis, Ioannina Medical School, University of Ioannina, Greece

### Professional Experience

Oct 1985 - Nov 1987: Obligatory service in the Greek Army  
 Nov 1986 - Nov 1987: House officer, Athens Navy Hospital (during my military service) (Director: Assistant Professor A. Perperas).  
 Nov 1987 - May 1988: Research Fellow, Unit of Gastrointestinal Endoscopy, Athens Navy Hospital (Director: Assistant Professor N. Nikolopoulos).  
 May 1988 - June 1989: Senior House officer, Division of Internal Medicine, Psychiatric Hospital of Attica (Director: Dr. A. Perrakis).  
 July 1989 - Dec 1990: Obligatory medical service in rural area (Health Center of Andros Island).

- January 1991 - May 1992: Honorary Research Fellow, Laboratory of Clinical Immunology, Department of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor H.M. Moutsopoulos).
- May 1992 - May 1995: Chief Resident, Division of Internal Medicine, Ioannina Medical School, University of Ioannina (Directors: Professor H.M. Moutsopoulos until Nov 1993 and then Professor D. Sideris) and Research Associate, Laboratory of Clinical Immunology, Department of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor H.M. Moutsopoulos).
- June 1995 – April 1996: Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- May 1996 - Feb 1997: Senior Registrar in Internal Medicine, Blood Bank at the University Hospital of Ioannina. (Director: Dr. E. Zervou) and Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- March 1997 – Oct 1997: Senior Registrar in Internal Medicine, Division of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos) and Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- Oct 1997 – Oct 1998: Post Doc Research Fellow in the Department of Gastroenterology and Hepatology, Hannover Medical School (Director: Professor M.P.Manns).
- Nov 1998 – Dec 2002: Assistant Professor of Medicine, University of Thessaly, Faculty of Health Sciences, Medical School\*.
- Jan 2003 – August 2008: Associate Professor of Medicine, University of Thessaly, Faculty of Health Sciences, Medical School\*.  
\*Chief of the Academic Liver Unit and 2<sup>nd</sup> Word of Internal Medicine Clinic, University Hospital of Larissa, Greece and Associate Director in the Research Lab of Internal Medicine, University of Thessaly, Medical School, Larissa, Greece since November 1998.
- June 2007 – June 2011: Head of the Research Group of Investigational Medicine, Institute of Biomedical Research & Technology, CERETETH, Larissa, Greece
- August 2008 – now: Professor of Medicine, Head of the Department of Medicine, the Academic Liver Unit and the Research Lab of Internal Medicine, University of Thessaly, Medical School, Larissa, Greece.

### **Licence to Practice Medicine and Speciality Certification**

- 1985 Certificate of Registration, as a Medical Practitioner (Ministry of Health, Athens, Greece).
- 1995 Certificate of Internal Medicine

### **Member of Societies**

- 1990 Society for Medical Studies (Greek)
- 1994 Hellenic Association for the Study of the Liver (Greek)
- 1996 Hellenic Society of Internal Medicine (Greek)

1996	The New York Academy of Sciences
1996	European Society for Free Radical Research
1997	European Association of Gastroenterology and Endoscopy
1997	Hellenic Association of Immunology (Greek)
1997	European Federation of Internal Medicine
1999	European Association for the Study of the Liver
2001	Hellenic Society of Systemic Autoimmune Diseases (Greek)
2001	California Blood Bank Society
2008	International Association for the Study of Liver Diseases (IASL)
2008	Hellenic Society of Internal Medicine of Northern Greece (Greek)
2013	American Association for the Study of Liver Diseases (AASLD)

## Awards

1. **Second award of new scientist** by the Hellenic Hypertension Society for the study entitled: *«Interleukin-1 $\beta$  in the systemic circulation of patients with familial hypercholesterolaemia and essential hypertension: additional risk factor for atheromatosis in hypertensive patients?»* presented in the 5th Panhellenic Congress in Hypertension (February 29-March 2, 1996) as well as in the 16th Scientific Meeting of the International Society of Hypertension (Glasgow, UK, June 23-27, 1996).
2. **Award of the best study** by the Hellenic Society of Gastroenterology for the study entitled: *«High concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptors (sIL-2Rs) in active ulcerative colitis after the development of a sensitive bioassay (IL-6 dependent mouse hybridoma clone B9)»* presented in the 10th World Congress of Gastroenterology, Los Angeles, October 2-7, 1994 (preliminary), as well as in the 16th Panhellenic Congress in Gastroenterology, Athens, October 12-16, 1996 (full version).
3. **First award** by the Balkan Clinical Laboratory Federation for the study entitled: *«Acute renal failure due to copper-induced rhabdomyolysis: Localisation of the injury by <sup>1</sup>H-NMR spectroscopy»* presented in the 5<sup>th</sup> Meeting of Balkan Clinical Laboratory Federation, Ioannina, October 9-12, 1997.
4. **Second award** in the 8<sup>th</sup> Hellenic Symposium on Hepatitis C entitled: *«Anticardiolipin antibodies (a-CLAbs) are not b2-GPI-dependent (non-thrombogenic a-CLAbs): preliminary results in 107 HCV patients from central Greece»* presented in Athens, January 27, 2001.
5. **First award** in poster session by the Hellenic Association for the Study of the Liver entitled: *«Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis»* presented in the 8<sup>th</sup> Panhellenic Congress of Hepatology, Thessaloniki, May 8-11, 2003.
6. **Award** by the Medical Association of Athens for the best research and practice in *“Autoimmune hepatitis and virus induced phenomena”*, Athens, May 2004.
7. **Award** for best oral presentation in the 10<sup>th</sup> Congress of the European Federation of Internal Medicine, entitled *«Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of patients»* presented in Athens, 5-8 October, 2011.
8. **Second Award** by the Hellenic Association for the Study of the Liver entitled: *“Decreased production of hepcidin in patients with autoimmune liver diseases”* presented in the 13<sup>th</sup> Panhellenic Congress of Hepatology, Rhodes, May 9-12, 2013.

## Other activities

1. **Official Member** of the **International Autoimmune Hepatitis Group** (2002-now).
2. **Reviewer** for Research Projects in Gastroenterology and Hepatology on behalf of **Wellcome Trust (England)**.
3. **Official peer reviewer for research projects of the University of Bologna (2013-now)**.
4. **Member** of the **Hepatitis Delta International Network**.
5. **Regular or Adhoc Reviewer for 67 journals**: Advances in Clinical Chemistry, Age & Ageing, Aging Clinical and Experimental Research, Alimentary Pharmacology & Therapeutics, Annals of Hepatology, Annals of Internal Medicine, Archivum Immunologiae et Therapiae Experimentalis, Arthritis Research & Therapy, Autoimmunity Highlights, BMC Gastroenterology, BMC Public Health, BMJ Case Reports, Book entitled “Framing the Knowledge of Viral Hepatitis” (Editor Dr. Raymond Schinazi), Cancer Investigation, Cell and Tissue Research, Clinica Chemica Acta, Clinical and Experimental Medicine, Clinical Immunology, Current Pharmaceutical Design, European Journal of Clinical Investigation, European Journal of Clinical Microbiology & Infectious Diseases, European Journal of Internal Medicine, Expert Opinion on Pharmacotherapy, Expert Review of Anti-infective Therapy, Expert Review of Gastroenterology and Hepatology, Expert Review of Molecular Diagnostics, Future Virology, Gastroenterology, GERMS (Official Journal of the European HIV/AIDS and Infectious Diseases Academy), Gut, Hellenic Journal of Gastroenterology (τόρα Annals of Gastroenterology), Hepatitis Monthly, Hepatology, Immunotherapy, International Journal of Artificial Organs, International Journal of Immunopathology and Pharmacology, International Journal of Infectious Diseases, International Journal of Medical Sciences, Iranian Red Crescent Medical Journal, Journal of Autoimmune Diseases, Journal of Bacteriology and Parasitology, Journal of Cancer Research and Therapeutics, Journal of Clinical Investigation, Journal of Clinical Pathology, Journal of Gastroenterology and Hepatology, Journal of Gastrointestinal and Liver Diseases, Journal of Hepatology, Journal of Infection, Journal of Laboratory and Clinical Medicine, Journal of Medical Virology, Journal of Postgraduate Medicine, Journal of Rheumatology, Journal of Veterinary Science, Journal of Viral Hepatitis, Journal of Virology and Microbiology, Liver International, Medical Science Monitor, Mediterranean Journal of Hematology and Infectious Diseases, Memorias do Instituto Oswaldo Cruz, Microbes and Infection, Mini – Reviews in Medicinal Chemistry, Molecular and Cellular Endocrinology, Ophthalmology, QJM, Scandinavian Journal of Gastroenterology, World Journal of Gastroenterology.
6. **Reviewer** on behalf of the **International Liver Congress (EASL, years 2011, 2012 and 2013)**
7. **Assistant Editor and Section Editor** in Immunology for the *Hellenic Journal of Gastroenterology* (1997 – 1999; now Annals of Gastroenterology).
8. **Member of the Editorial Board and Section Editor** for Autoimmune Liver Diseases and Virus Induced Autoimmunity in the *Journal of Autoimmune Diseases* (2004-2009).
9. **Member of the Editorial Board** of *Journal of Hepatology* (2007-2009 and 2010-now).
10. **Member of the Editorial Board** of *Liver International* (2008-2012).
11. **Member of the Editorial Board** of *World Journal of Gastroenterology* (2007-2009).
12. **Member of the Editorial Board** of *Autoimmune Diseases* (2009-now).
13. **Member of the Editorial Board** of *World Journal of Gastrointestinal Pathophysiology* (2011-2015).
14. **Member of the Editorial Board** of *World Journal of Hepatology* (2013-now).

15. **Participant investigator** of the European Collaborative Study on the Incidence of Inflammatory Bowel Disease (10. 1991 - 9. 1993) published in *Gut, European Journal of Gastroenterology and Hepatology and Inflammatory Bowel Disease* in 1996, 1997 and 1998 respectively (see International Publications No: 22, 25, 27).
16. **Participant principal investigator** in a local (Greek) randomised controlled trial for the treatment of naïve HCV patients with pegylated interferon-a2b plus ribavirin published in *J Gastrointestin Liver Dis* (see International Publications No: 79).
17. **Participant principal investigator** in the collaborative study with Professor J-M Pawlotsky, University of Paris, France regarding the Clinical Significance of hepatitis B virus DNA levels in HBeAg-negative, HBV-genotype D-infected patients published in *Hepatology 2004; 40(Suppl.1):675A, Journal of Clinical Virology 2006; 36 (Suppl.): S78, Journal of Hepatology 2005; 42 (Suppl.): 489*.
18. **Collaboration** with Professor D. Vergani (King's College London) and Professor J. Rodes (Barcelona, Spain) on the prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis published in *Gut* (see International Publications No: 61), on the clinical significance of isotype specific antimitochondrial antibodies in primary biliary cirrhosis published in *Liver International* (see International Publications No: 100) on the clinical significance of anti-gp210 antibodies published in *Hepatology* (see International Publications No: 97) and on the significance and correlation of AMA detected by indirect immunofluorescence and immunoblot published in *Liver International* (see International Publications No: 95).
19. Sponsor and **principal investigator** along with Professor M.P. Manns (Hannover, Germany) and Professor C. Yurdaydin (Ankara, Turkey) on Investigator Protocol entitled: "A multicenter randomized study comparing the efficacy of adefovir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adefovir dipivoxil plus pegylated interferon-alfa-2a for the treatment of chronic delta hepatitis", published in *Liver International, New England Journal of Medicine, Antiviral Therapy, Journal of Viral Hepatitis & Turkish Journal of Gastroenterology* (see International Publications No: 124,133,141,145,150).
20. **Collaboration** with Prof. M.P. Manns (Hannover, Germany) and Prof. H. Tillmann (Leipzig, Germany) on the safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience, which is published in *Journal of Viral Hepatitis* (see International Publications No: 74).
21. **Participant principal investigator** in the "Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients with Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options (GS-01-550)", which has been completed in March 2004.
22. **Participant principal investigator** in a multicenter, double blinded study in patients with chronic hepatitis C who are non-responders to prior peginterferon-a or peginterferon-a + ribavirin therapy comparing treatment with thymosin a1 + peginterferon-a-2a plus ribavirin with peginterferon-a-2a + ribavirin + placebo (2005-2008, Co-ordinator: Professor M. Rizzetto).
23. **Participant principal investigator** in a multicenter, double blinded study on Tenofovir vs Adefovir in the treatment of naïve patients with chronic anti-HBe positive hepatitis B (2006-now; we have been audited for this study by American authorities funded by Gilead with excellent conclusions).
24. **Participant principal investigator** in a multicenter, Phase 3b, randomized, double-blind, double-dummy study, evaluating the antiviral efficacy, safety, and tolerability of Tenofovir Disoproxil Fumarate monotherapy versus Emtricitabine plus Tenofovir DF fixed-dose

combination therapy in subjects with chronic hepatitis B who are resistant to lamivudine (2009-2010).

25. **Collaboration** with Prof. M.P. Manns (Hannover, Germany) and Prof. H. Wedemeyer (Hannover, Germany) on the cross-genotype reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073 which is published in *Vaccine* (see International Publications No: 112).
26. **Partner (member)** of the E-RARE “Epinostics” Consortium of Europe (2007-10) entitled: “Autoimmune liver diseases: Epitope peptide mapping – The entry to novel and innovative diagnostic and therapeutic applications” funded by European Union (740,000 €).
27. **Participant principal investigator** in a multicentre study of the International Autoimmune Hepatitis Group regarding the development of the simplified criteria for the diagnosis of autoimmune hepatitis published in *Hepatology* (see International Publications No: 103).
28. **Participant principal investigator** in a multicentre study regarding the prompt, rapid and safe detection of IgG and IgA antimitochondrial and ANA-PBC specific antibodies which is published in *Journal of Autoimmunity* (see International Publications No: 130).
29. **Participant principal investigator** in a study with industry (Boca Biolistics, USA) entitled «Hepatitis B, Hepatitis C and HIV sample collection study» (BB-ID-034, 2011-now).
30. **Participant principal investigator** in a study entitled: “Multicenter, Open-Label, study of Telaprevir in Combination with Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects with Severe Fibrosis and Compensated Cirrhosis” (VX-950HEP3002, 2012-now).
31. **Participant principal investigator** in a study entitled: “A phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs telaprevir, both in combination with Peg-IFN $\alpha$ -2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior Peg-IFN $\alpha$  and ribavirin therapy” (TMC435HPC3001, 2012-now).
32. **Participant principal investigator** in a study entitled: “Non-Inteventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C” (MV25599, 2012-now).
33. **Participant principal investigator** in a study entitled: “An international, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics” (MV25600, 2012-now).
34. **Participant principal investigator** in a multicentre study regarding the detection of new gene loci for primary sclerosing cholangitis which is published in *Nature Genetics* (see International Publications No: 159).
35. **Participant principal investigator** in a study entitled: “EU-CORE: European Registry of Outcome and Experience from CUBICIN use for the treatment of severe infections from Gram positive bacteria” (CCBC134A2403, 2011-2012).
36. **Participant principal investigator** in a study entitled: “A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of additional LDL-Cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease” (2013-now).
37. **Reviewer** for Research Projects in Gastroenterology and Hepatology on behalf of the Hellenic Central Council of Health (*Committee of Biomedical Research*).
38. **Reviewer** for Research Projects on behalf of the Hellenic Ministry of Education.

39. **Member** of the Scientific Committee for the Prevention, Diagnosis, Management and Treatment of Viral Hepatitis, Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health (2000-now).
40. **Associate member** of the Governing Board of the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health (2002-2005).
41. **Vice President** of the Committee for the Control of Infectious Diseases in the University Hospital of Larissa, Greece (2004-2007).
42. **Member** of the Governing Board of the Hellenic Association for the Study of the Liver (2001-2003).
43. **Member** of the Data Safety Monitoring Board of the German Bundesministry of Education and Research for the GAHB-Study.
44. **Recognition (2013)** of the Department of Medicine, the Liver Unit and the Research Laboratory of Internal Medicine, Medical School, University of Thessaly **by the Hellenic Center for Disease Control and Prevention as a Specific Center of Rare Diseases (Autoimmune Hepatitis)**.
45. **Member of the Advisory Board and Steering Committee for the publication of the Clinical Practice Guidelines for the management of chronic viral hepatitis B and C** by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health (2013).
46. **Vice President** of the Hellenic Association for the Study of the Liver (2013-2015).
47. **President** of the Hellenic Association for the Study of the Liver (2015-2017).

## BIBLIOGRAPHY

### A. Thesis

#### *Doctoral Thesis*

«*Inflammatory Bowel Disease: Immunologic abnormalities*», Ioannina, 1995.

Parts of my Doctoral Thesis have been published as full papers in *Gut*, *European Journal of Internal Medicine* and *European Journal of Gastroenterology and Hepatology* (see International Publications No: 1,4,19 and 28).

### B. Papers in International Medical Journals

1. **G.N. Dalekos**, M.N. Manoussakis, A.C. Goussia, E.V. Tsianos, H.M. Moutsopoulos. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. *Gut* 34: 658-664, 1993.
2. **G.N. Dalekos**, M.N. Manoussakis, E. Zervou, E.V. Tsianos, H.M. Moutsopoulos. Immunologic and viral markers in the circulation of anti-HIV negative heroin addicts. *Eur J Clin Invest* 23: 219-225, 1993.
3. E.V. Tsianos, **G.N. Dalekos**, M. Elisaf, E. Zervou, K.C. Siamopoulos. High frequency of antibodies to Hantaan virus and hepatitis C virus in haemodialysis patients. Coincidence or cross reaction? *J Intern Med* 234: 607-610, 1993.
4. E.V. Tsianos, C.N. Masalas, M. Merkouropoulos, **G.N. Dalekos**, R.F. Logan. Incidence of inflammatory bowel disease in north west Greece: Rarity of Crohn's disease in an area where ulcerative colitis is common. *Gut* 35: 369-372, 1994.

5. **G.N. Dalekos**, E.V. Tsianos: Antineutrophil antibodies in chronic viral hepatitis. *J Hepatol (Letter)* 20: 561, 1994.
6. E.V. Tsianos, **G.N. Dalekos**, M.H. Merkouropoulos, A. Tsatsoulis, K.I. Seferiadis. Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. *Eur J Gastroenterol Hepatol* 6: 547-551, 1994.
7. **G.N. Dalekos**, G.C. Liapi, P. Dallas, D. Stefanou, M. Elisaf: Stauffer's syndrome as first manifestation of renal cell carcinoma. A case report. *Eur J Intern Med* 5: 319-320, 1994.
8. E.V. Tsianos, **G.N. Dalekos**, C. Tzermias, M.H. Merkouropoulos, J. Hatzis. Hidradenitis suppurativa in Crohn's disease. A further support to this association. *J Clin Gastroenterol* 20: 151-153, 1995.
9. P.G. Vlachoyiannopoulos, **G.N. Dalekos**, A. Tsatsoulis: Transient hyperthyroidism following lower respiratory tract infections. A clinical observation. *Eur J Intern Med* 6: 19-22, 1995.
10. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. IgM antibodies to HCV in chronic active hepatitis in NW Greece. Solution or more questions? *J Hepatol (Letter)* 22: 509, 1995.
11. **G.N. Dalekos**, E. Zervou, F. Karabini, K. Bourantas, M. Elisaf, K.C. Siamopoulos. Prevalence of antibodies to human T-lymphotropic virus types I and II in volunteer blood donors and high risk groups in northwestern Greece. *Transfusion* 35: 503-506, 1995.
12. **G.N. Dalekos**, E. Zervou, F. Karabini, E.V. Tsianos. Prevalence of viral markers among refugees from southern Albania: increased incidence of infections with hepatitis A, B and D viruses. *Eur J Gastroenterol Hepatol* 7: 553-558, 1995.
13. C. Tzermias, **G.N. Dalekos**, J. Hatzis, E.V. Tsianos: Pyoderma gangrenosum: successful treatment with intralesional injections of corticosteroids. *J Eur Acad Dermatol Venerol (Letter)* 5: 197-199, 1995.
14. A. Tsatsoulis, P.G. Vlachoyiannopoulos, **G.N. Dalekos**, E.O. Johnson, H.M. Moutsopoulos. Increased serum interleukin-1 $\beta$  (IL-1 $\beta$ ) during treatment of hyperthyroidism with antithyroid drugs. *Eur J Clin Invest* 25: 654-658, 1995.
15. **G.N. Dalekos**, F.N. Skopouli, E.V. Tsianos. Primary biliary cirrhosis associated with anticardiolipin syndrome. *Eur J Intern Med* 6: 179-181, 1995.
16. **G.N. Dalekos**, E. Zervou, M.H. Merkouropoulos, E.V. Tsianos. Prevalence of hepatitis B and C viruses infection in chronic alcoholics with or without liver disease in Ioannina, Greece: Low incidence of HCV infection. *Eur J Epidemiol* 12: 21-25, 1996.
17. N.V. Angelopoulos, Chr. Mantas, **G.N. Dalekos**, K. Vasalos, E.V. Tsianos. Psychiatric factors in patients with ulcerative colitis according to disease activity. *Eur J Psychiat* 10: 87-99, 1996.
18. **G.N. Dalekos**, C. Papas, L.G. Christou, J. Pneumaticos, G. Nakos. Severe erysipelas in a previously healthy man: possible link with Epstein-Barr virus infection. *Eur J Intern Med* 7: 53-56, 1996.
19. **G.N. Dalekos**, E.V. Tsianos, H.M. Moutsopoulos. Immunologic markers of disease activity in the circulation of patients with ulcerative colitis: high concentrations of soluble interleukin-2 receptor molecules and interleukin-6 in active disease. *Eur J Intern Med* 7: 93-98, 1996.
20. **G.N. Dalekos**, M. Elisaf, N. Papagalanis, Chr. Tzallas, K.C. Siamopoulos. Elevated interleukin-1 $\beta$  in the circulation of patients with essential hypertension before any drug therapy: A pilot study. *Eur J Clin Invest* 26: 936-939, 1996.

21. **G.N. Dalekos**, E. Zervou, K. Bourantas, E.V. Tsianos. Viral hepatitis and idiopathic (autoimmune) thrombocytopenic purpura. Is there any relationship? *J Hepatol (Letter)*, 25: 1000-1001, 1996.
22. S. Shivananda, J Lennard-Jones, R. Logan, N. Fear, A. Price, L. Carpenter, M. van Blankenstein, S. Shivananda, J Lennard-Jones, R. Logan, N. Fear, A. Price, L. Carpenter, M. van Blankenstein, S. Bjornsson, J.H. Johansson, E. Oddsson, B. Moum, M. Vatn, E. Aadland, O. Fausa, I. Lygren, J. Sauar, T. Schulz, N. Stray, R. Stave, E. Langholz, V. Binder, P. Vedtofte, J. Sonne, R. Collins, C. Omorain, J. Mayberry, I. Carr, M. Russel, R. Stockbrugger, H. Goebell, B. Katschinski-Breuer, J.L. Dupas, P. Bianchi, T. Ranzi, M.C. Campannini, M. Curzio, R. Gullotta, P. Bodoni, P. Politi, G. Lupinacci, A. Zambelli, G. Fornaciari, M. Beltrami, M.G. Mortilla, F. Nicoli, L. Serra, G. Trallori, A. Bonanomi, G. dAlbasio, F. Pacini, V.R. Ochoa, A. delaFuente, F. Tardaguila, D.D. Rodriguez, S. Pereira, D.M. Butron, D.M. Cueto, L. Alvarez Cervea, J. Clofent, J.R. Pineda, E. Brullet, X. Bonfill, G. Urrutia, F.T. Veloso, R. Noronha, E. Tsianos, **G. Dalekos**, E. Monteiro, J. Freitas, P.Borralho, F.C. Leal, C. Soares, P. Martins, M. Dupond, M. Cottone, G. Filippazzo, R. Ayala, J. Mouzas, O. Manousos, S. Odes, R. Brower, J. Campbell, R. Doll, A. Ekbom. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative study on Inflammatory Bowel Disease (EC-IBD). *Gut* 39: 690-697, 1996.
23. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, O. Tsolas, K.C. Siamopoulos. Increased serum levels of interleukin-1 $\beta$  in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? *J Lab Clin Med* 129: 300-308, 1997. (Original article with Editorial).
24. K.L. Bourantas, L.G. Christou, **G.N. Dalekos**, K. Barbati, E.V. Tsianos. A 54-year-old stock-breeder with ascites. *Lancet* 349: 994, 1997.
25. J. E. Lennard-Jones, S. Shivananda, N. Fear, L. Carpenter, M. van Blankenstein, S. Bjornsson, J.H. Johansson, E. Oddsson, B. Moum, M. Vatn, E. Aadland, O. Fausa, I. Lygren, J. Sauar, T. Schulz, N. Stray, R. Stave, E. Langholz, V. Binder, P. Vedtofte, J. Sonne, R. Collins, C. Omorain, J. Mayberry, I. Carr, M.G.V.M. Russel, R. Stockbrugger, H. Goebell, B. Katschinski-Breuer, J.L. Dupas, P. Bianchi, T. Ranzi, M.C. Campannini, M. Curzio, R. Gullotta, P. Bodoni, P. Politi, G. Lupinacci, A. Zambelli, G. Fornaciari, M. Beltrami, M.G. Mortilla, F. Nicoli, L. Serra, G. Trallori, A. Bonanomi, G. dAlbasio, F. Pacini, V.R. Ochoa, A. delaFuente, F. Tardaguila, D.D. Rodriguez, S. Pereira, D.M. Butron, D.M. Cueto, L. Alvarez Cervea, J. Clofent, J.R. Pineda, E. Brullet, X. Bonfill, G. Urrutia, F.T. Veloso, R. Noronha, E. Tsianos, **G. Dalekos**, E. Monteiro, J. Freitas, P.Borralho, F.C. Leal, C. Soares, P. Martins, M. Dupond, M. Cottone, G. Filippazzo, R. Ayala, J. Mouzas, O. Manousos, S. Odes, R. Brower, J. Campbell, R. Doll, A. Ekbom, Logan RF, Price AB. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. *Eur J Gastroenterol Hepatol* 9: 353-359, 1997.
26. **G.N. Dalekos**, J. Hatzis, E.V. Tsianos. Dermatologic disease during interferon-alpha therapy for chronic viral hepatitis. *Ann Intern Med (Letter)* 128: 409-410, 1998.
27. M.G.V.M. Russel, A. Volovics, E.J. Schoon, E.H.J. van Wijlick, R.F. Logan, S. Shivananda, R. Stockbrugger, E. Langholz, V. Binder, J.L. Dupas, H. Goebell, B. Katschinski-Breuer, E. Tsianos, **G. Dalekos**, J. Mouzas, O. Manousos, S. Bjornsson, E. Oddsson, S. Odes, C. O'Morain, R. Collins, P. Bianchi, T. Ranzi, P. Bodoni, P. Politi, M. Cottone, G. Fornaciari, M. Beltrami, G. Trallori, A. Bonanomi, M. Vatn, B. Moum, F.T. Veloso, R. Noronha, E. Monteiro, J. Freitas, E. Brullet, X. Bonfill, V.R. Ochoa, A. de la Fuente, J. Mayberry, I. Carr. Inflammatory bowel disease: Is there any relation between smoking status and disease presentation? *Inflamm Bowel Dis* 4: 182-186, 1998.

28. **G.N. Dalekos**, J. Ringstad, J. Savaidis, K.I. Seferiadis, E.V. Tsianos. Zinc, copper and immunologic markers in the circulation of well-nourished patients with ulcerative colitis. *Eur J Gastroenterol Hepatol* 10: 331-337, 1998.
29. **G.N. Dalekos**, E. Zervou, M. Elisaf, N. Germanos, K. Bourantas, E. Galanakis, K.C. Siamopoulos, E.V. Tsianos. Antibodies to hepatitis E virus among different populations in Greece: increased prevalence in an haemodialysis unit. *Transfusion* 38: 595-598, 1998.
30. **G.N. Dalekos**, D.S. Boumba, K. Katopodis, E. Zervou, G. Sferopoulos, M. Elisaf, E.V. Tsianos, K.C. Siamopoulos. Absence of viraemia due to HCV in anti-HCV negative haemodialysis patients. *Nephrol Dial Transpl* 13: 1804-1806, 1998.
31. K.L. Bourantas, **G.N. Dalekos**, A. Makis, A. Chaidos, S. Tsiara, A. Mavridis. Acute phase proteins and interleukins in steady state sickle cell disease. *Eur J Haematol* 61: 49-54, 1998.
32. **G.N. Dalekos**, K. Achenbach, D. Christodoulou, G.K. Liapi, E. Zervou, D. Sideris, E.V. Tsianos. Idiopathic dilated cardiomyopathy: lack of association with hepatitis C virus infection. *Heart* 80: 270-275, 1998.
33. **G.N. Dalekos**, D. Christodoulou, K. G. Kistis, J. Hatzis, E.V. Tsianos. A prospective evaluation of dermatologic side effects during interferon-alpha therapy for chronic viral hepatitis. *Eur J Gastroenterol Hepatol* 10:933-939, 1998.
34. **G.N. Dalekos**, E. Zervou, M. Elisaf, D.S. Boumba, K. Katopodis, G. Sferopoulos, K.C. Siamopoulos, E.V. Tsianos. Increased prevalence of markers of GBV-C/HGV infection in a selected cohort of haemodialysis patients negative for other blood-borne viruses. *Nephrol Dial Transpl (Letter)*, 14: 255-256, 1999.
35. **G.N. Dalekos**, H. Wedemeyer, P. Obermayer-Straub, A. Kayser, A. Barut, H. Frank, M.P. Manns. Epitope mapping of cytochrome P450 2D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. *J Hepatol* 30: 366-375, 1999.
36. M. Fatouros, **G.N. Dalekos**, E. Mylonakis, G. Vekinis, A. Kapas. Alterations in body weight, breaking strength and wound healing in Wistar rats treated pre- and postoperatively with erythropoietin or granulocyte-macrophage colony stimulating factor: Evidence of a previously unknown anabolic effect of erythropoietin? *J Lab Clin Med* 133: 253-259, 1999.
37. **G.N. Dalekos**, K. Kistis, D. Boumba, E. Zervou, P. Voulgari, A.A. Drosos, E.V. Tsianos. Increased incidence of anticardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to antiphospholipid syndrome. *Eur J Gastroenterol Hepatol* 12: 67-74, 2000.
38. **G.N. Dalekos**, E. Galanakis, E. Zervou, M. Tzoufi, P.L. Lapatsanis, E.V. Tsianos. Interferon-alpha treatment of children with hepatitis D virus infection: The Greek experience. *Hepatology*, 47: 1072-1076, 2000.
39. E.K. Zervou, **G.N. Dalekos**, D.S. Boumba, E.V. Tsianos. Value of anti-HBc screening of blood donors for prevention of HBV infection: Results of a three year prospective study in northwestern Greece. *Transfusion*, 41: 652-658, 2001.
40. **G.N. Dalekos**, K. Zachou, Ch. Liaskos. The antiphospholipid syndrome and infection. (**Invited review**). *Curr Rheumatol Reports*, 3: 277-285, 2001.
41. D.K. Christodoulou, **G.N. Dalekos**, M. Merkouropoulos, K.G. Kistis, G. Georgitsi, E. Zervou, K. Zachou, E.V. Tsianos. Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice. *Eur J Intern Med*, 12: 435-441, 2001.

42. P. Obermayer-Straub, S. Braun, A. Kayser, A. Barut, S. Loges, A. Harms, C. Strassburg, **G. Dalekos**, J. Perheentupa, M.P. Manns. Hepatic autoantigens in patients with autoimmune polyendocrine syndrome type 1 (APS1). *Gastroenterology* 121:668-677, 2001.
43. **G.N. Dalekos**, E. Makri, S. Loges, P. Obermayer-Straub, K. Zachou, Th. Tsikrikas, E. Schmidt, G. Papadamou, M.P. Manns. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of HCV patients from central Greece. *Eur J Gastroenterol Hepatol* 14:35-42, 2002.
44. **G.N. Dalekos**, K. Zachou, C. Liaskos, N. Gatselis. Autoantibodies and defined target-autoantigens in autoimmune hepatitis: An overview. *Eur J Intern Med* 13:293-303, 2002.
45. K. Zachou, C. Liaskos, D.K. Christodoulou, M. Kardasi, G. Papadamou, N. Gatselis, S.P. Georgiadou, E.V. Tsianos and **G.N. Dalekos**. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I co-factor or features of antiphospholipid syndrome. *Eur J Clin Invest* 33:161-168, 2003.
46. E. Zervou, D.S. Boumba, Ch. Liaskos, S. Georgiadou, E.V. Tsianos, **G.N. Dalekos**. Low prevalence of HCV, HIV and HTLV-I/II infection markers in northwestern Greece: Results of a three year prospective donor study. *Eur J Intern Med* 14:39-44, 2003.
47. A. Polyzos, C. Sinani, N. Kelekis, G. Papadamou, K. Patsiaoura, and **G.N. Dalekos**. Advanced-stage intrahepatic cholangiocarcinoma in a patient with end-stage HCV-associated liver disease. *Eur J Gastroenterol Hepatol* 15:331-334, 2003.
48. D.S. Kyriakou, M.G. Alexandrakis, K. Zachou, F. Passam, N.E. Stathakis and **G.N. Dalekos**. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Hepatol* 39:679-685, 2003.
49. **G.N. Dalekos**, P. Obermayer-Straub, M. Bartels, T. Maeda, A. Kayser, S. Loges, S. Braun, E. Schmidt, M.E. Gershwin, M.P. Manns. Cytochrome P450 2A6: A new hepatic autoantigen in chronic hepatitis C virus infection. *J Hepatol* 39:800-806, 2003. **(Original article with Editorial)**.
50. K. Zachou, E. Rigopoulou, C. Liaskos, K. Patsiaoura, E. Makri, N. Stathakis, and **G.N. Dalekos**. Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. *Eur J Gastroenterol Hepatol* 16:425-428, 2004.
51. N. Kelekis, E. Makri, A. Vasiou, K. Patsiaoura, M. Spiridakis and **G.N. Dalekos**. Confluent hepatic fibrosis as the presenting imaging sign in non-advanced alcoholic cirrhosis. *Clin Imaging* 28:124-127, 2004.
52. S.P. Georgiadou, K. Zachou, C. Liaskos, E. Rigopoulou, F. Gerovasilis, E. Makri, **G.N. Dalekos**. Occult hepatitis B virus (HBV) infection in Greek patients with chronic hepatitis C and diverse non-viral hepatic diseases. *J Viral Hepat* 11:358-365, 2004.
53. E. Rigopoulou, **G.N. Dalekos**. Anti-sp100 antibodies in primary biliary cirrhosis. *Scand J Gastroenterol* 39:406-407, 2004.
54. A.N. Moulas, A. Noulas, E. Makri, S. Bonanou-Tzedaki, and **G.N. Dalekos**. Total antioxidant status and erythrocyte superoxide dismutase activity in patients with chronic hepatitis B and C. *Eur J Inflam* 2:77-84, 2004.
55. K. Zachou, E. Rigopoulou, and **G.N. Dalekos**. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. *J Autoim Dis* 1:2, 2004 (15 October 2004) **(Invited Review)**.
56. E. E. Yiannaki, E. Zintzaras, A. Analatos, C. Theodoridou, **G.N. Dalekos**, A.E. Germenis. Evaluation of a microsphere-based flow cytometric assay for diagnosis of celiac disease. *J Immunoassay Immunochem* 25:345-357, 2004.

57. I. Stefanidis, E.K. Zervou, Ch. Rizos, Ch. Syrganis, E. Patsidis, G. Kyriakopoulos, L. Sdrakas, N. Tsianas, Rigopoulou EI, Liakopoulos V, **G.N. Dalekos**. Hepatitis E virus antibodies in hemodialysis patients: an epidemiological survey in central Greece. *Int J Artif Organs* 27:842-847, 2004.
58. E.K. Zervou, S. Georgiadou, M. Tzilianos, P. Georgitsi, V. Pournara, S. Nousis, C. Pappas, L. Daskalou, A. Vrettou, F. Karabini, and **G.N. Dalekos**. Human T-lymphotropic virus type-I/II infections in volunteer blood donors of north and west Greece. *Eur J Intern Med* 15:422-427, 2004.
59. N.K. Gatselis, S.P. Georgiadou, N. Tassopoulos, K. Zachou, C. Liaskos, A. Hatzakis, and **G.N. Dalekos**. Impact of parietal cell autoantibodies (PCA) and non-organ specific autoantibodies (NOSA) on the treatment outcome of patients with HCV infection: a pilot study. *World J Gastroenterol* 11:482-487, 2005.
60. A. Tsikrikoni, D.S. Kyriakou, E.I. Rigopoulou, M.G. Alexandrakis, K. Zachou, F. Passam, **and G.N. Dalekos**. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Hepatol* 42:393-399, 2005.
61. E.I. Rigopoulou, E.T. Davies, A. Pares, K. Zachou, C. Liaskos, D.P. Bogdanos, J. Rodes, **G.N. Dalekos**, D. Vergani. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. *Gut* 54:528-532, 2005.
62. C. Liaskos, E. Rigopoulou, K. Zachou, S. Georgiadou, N. Gatselis, **and G.N. Dalekos**. Prevalence and clinical significance of anticardiolipin antibodies in patients with autoimmune hepatitis type 1. *J Autoimmun* 24:251-260, 2005.
63. A. Stefanidis, S.P. Georgiadou, C. Gioti, A. Loukopoulos, M. Ioannou, S. Pournaras, **and G.N. Dalekos**. Leptospirosis and pancytopenia: Two case reports and review of the literature. *J Infection* 51:e277-280, 2005.
64. M. Satra, **G.N. Dalekos**, P. Kollia, N. Vamvakopoulos, A. Tsezou. Telomerase reverse transcriptase mRNA expression in peripheral lymphocytes of patients with chronic HBV and HCV infections. *J Viral Hepat* 12:488-493, 2005.
65. E.K. Zervou, S.P. Georgiadou, G.K. Liapi, F. Karabini, V. Giogiakas, K. Zisiadis, N.K. Gatselis, I. Goudevenos **and G.N. Dalekos**. Hepatitis viruses and human T-lymphotropic virus type I/II infection markers in patients underwent an open-heart surgery: *Evidence of increased risk for exposure to HBV and HEV*. *Eur J Intern Med* 16:424-428, 2005.
66. E.K. Zervou, N.K. Gatselis, E. Xanthi, K. Ziciadis, **and G.N. Dalekos**. Intrafamilial spread of hepatitis B virus infection in Greece. *Eur J Gastroenterol Hepatol* 17:911-915, 2005.
67. E.I. Rigopoulou, I. Stefanidis, C. Liaskos, E.K. Zervou, C. Rizos, P. Mina, K. Zachou, C. Syrganis, E. Patsidis, G. Kyriakopoulos, L. Sdrakas, N. Tsianas **and G. N. Dalekos**. HCV RNA qualitative assay based on transcription-mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece. *J Clin Virol* 34:81-85, 2005.
68. A.E. Germanis, E.E. Yiannaki, K. Zachou, V. Roka, S. Barbanis, C. Liaskos, K. Adam, A.N. Kapsoritakis, S. Potamianos, **G.N. Dalekos**. Prevalence and clinical significance of IgA antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. *Clin Diag Lab Immunol* 12:941-948, 2005.
69. K. Zachou, E. Rigopoulou, A. Tsikrikoni, M. Alexandrakis, F. Passam, D. Kyriakou, N. Stathakis **and G.N. Dalekos**. Cytokines production is distinct in bone marrow cultures from

patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Autoimmun* 25:283-288, 2005.

70. I. Stefanidis, V. Liakopoulos, E.I. Rigopoulou, **G.N. Dalekos**. Diagnostic discordance for hepatitis C virus infection in hemodialysis: correlations with clinical and laboratory features. *Am J Kidney Dis (Letter)* 46:992-993, 2005.
71. I. Nikaina, C. Pastaka, K. Zachou, **G.N. Dalekos**, K. Gourgoulianis. Sleep apnoea syndrome and early stage cirrhosis: a pilot study. *Eur J Gastroenterol Hepatol* 18:31-35, 2006.
72. N. Gatselis, E. Malli, G. Papadamou, E. Petinaki, **and G.N. Dalekos**. Direct detection of *Cardiobacterium hominis* in serum from a patient with infective endocarditis by broad-range bacterial PCR. *J Clin Microbiol* 44:669-672, 2006.
73. N. Tzovaras, A. Stefos, S.P. Georgiadou, N. Gatselis, G. Papadamou, E. Rigopoulou, M. Ioannou, I. Skoularigis **and G.N. Dalekos**. Reversion of severe hepatopulmonary syndrome in a non-cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: A case report and review of the literature. *World J Gastroenterol* 12:336-339, 2006.
74. H.L. Tillmann, J. Hadem, L. Leifeld, K. Zachou, A. Canbay, C. Eisenbach, I. Graziadei, J. Encke, H. Schmidt, W. Vogel, A. Schneider, U. Spengler, G. Gerken, **G.N. Dalekos**, H. Wedemeyer, M.P. Manns. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. *J Viral Hepat* 13:256-63, 2006.
75. T.A. Zografos, E.I. Rigopoulou, C. Liaskos, E. Togousidis, K. Zachou, N. Gatselis, A. Germanis **and G. N. Dalekos**. Alterations of leptin during IFN-a therapy in patients with chronic viral hepatitis. *J Hepatol* 44:848-55, 2006.
76. Zachou K, Liaskos C, Rigopoulou E, Gabeta S, Papamichalis P, Gatselis N, Georgiadou S, **and G.N. Dalekos**. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. *Clin Immunol* 119:203-212, 2006.
77. E.I. Rigopoulou, S.P. Georgiadou, S. Barbanis, **G.N. Dalekos**. Lack of association between appendectomy and primary biliary cirrhosis (PBC). *Scand J Gastroenterol* 41:573-576, 2006.
78. D.P. Bogdanos, C. Liaskos, E.I. Rigopoulou, **G.N. Dalekos**. Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. *Clin Chim Acta (Letter)* 373:183-184, 2006.
79. K. Mimidis, V.P Papadopoulos, I. Elefsiniotis, D. Kolioukas, I. Ketikoglou, E. Paraskevas, S. Kanatakis, D. Chrysagis, **G.N Dalekos**, C. Tzathas, A. Protopapas, E. Gigi, E. Tsianos, G. Kartalis. Hepatitis C virus survival curve analysis in naïve patients treated with peg-interferon a-2b plus ribavirin. A randomized controlled trial for induction with high doses of peg-interferon and predictability of sustained viral response from early virologic data. *J Gastrointestin Liver Dis* 15: 213-219, 2006.
80. N. Stefanou, M. Satra, V. Papanikolaou, F. Kalala, N. Gatselis, A. Germanis, **G.N. Dalekos**, A. Tsezou. Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. *Exp Biol Med* 231:1653-1663, 2006.
81. E.Petinaki and **G.N. Dalekos**. Molecular methods as tools for the diagnosis of bacterial infections: useful or useless? *Res Adv Microbiology* 6:23-31, 2006. **(Invited review)**.
82. A.I. Papaioannou, K. Kostikas, N. Tzovaras, T.S. Kiropoulos, A. Loukopoulos, M.G. Ioannou, F. Karasavvidou, **G.N. Dalekos**, K.I. Gourgoulianis. Mantle Cell Lymphoma Presenting With Persistent Pleural Effusion And Severe Thrombocytopenia. *The Internet Journal of Pulmonary Medicine* 6: 2, 2006.

83. E. Tsironi, N. Gatselis, M.G. Kotoula, D. Z. Chatzoulis, **G.N. Dalekos**. Unexplained choroidal embolization: Remember the antiphospholipid syndrome. *Lancet* 368:1936, 2006.
84. **G.N. Dalekos**, K. Makaritsis, E.I. Rigopoulou. Redesigning training for internal medicine. What needs to be done? *Ann Intern Med (Letter)* 145:865, 2006.
85. P. Guéguen, **G. Dalekos**, J-B Noursbaum, K. Zachou, Putterman C, Youinou P, Renaudineau Y. Double reactivity against actin and  $\alpha$ -actinin defines a severe form of autoimmune hepatitis type 1. *J Clin Immunol* 26: 495-505, 2006.
86. N.K. Gatselis, S.P. Georgiadou, G.K. Koukoulis, N.Tassopoulos, K. Zachou, C. Liaskos, A. Hatzakis, **G.N. Dalekos**. Clinical significance of organ and non-organ specific autoantibodies on the response to antiviral treatment of patients with chronic hepatitis C. *Aliment Pharmacol Ther* 24:1563-1573, 2006.
87. M. Satra, N. Gatselis, D. Iliopoulos, D. Zacharoulis, **G.N. Dalekos**, A. Tsezou. Real time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. *J Viral Hepat* 14:41-7, 2007.
88. C. Liaskos, D.P. Bogdanos, E.T. Davies, **G.N. Dalekos**. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. *J Clin Pathol (Letter)* 60:107-108, 2007.
89. N.K. Gatselis, E. Rigopoulou, A. Stefos, M. Kardasi, **and G.N. Dalekos**. Risk factors associated with HCV infection in semi-rural areas of central Greece. *Eur J Intern Med* 18:48-55, 2007.
90. E.I. Rigopoulou, M. Mytilinaiou, O. Romanidou, C. Liaskos, **G.N. Dalekos**. Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. *J Autoimmune Dis* 4(1): 2, 2007.
91. C. Liaskos, D.P. Bogdanos, E.I. Rigopoulou, **G.N. Dalekos**. Development of anti-mitochondrial antibodies in patients with autoimmune hepatitis: an art of facts or an artifact? *J Gastroenterol Hepatol (Letter)* 22:454-455, 2007.
92. N.K. Gatselis, A. Stefos, C. Gioti, E.I. Rigopoulou and **G.N. Dalekos**. Primary biliary cirrhosis and Henoch-Schonlein purpura: Report of two cases and review of the literature. *Liver Int* 27:280-283, 2007.
93. A. Daponte, M. Ioannou, C. Gioti, A. Kallitsaris, **G.N. Dalekos**, I.E. Messinis. Primary retroperitoneal non-Hodgkin lymphoma presenting with torturous generalized pruritus in an elderly. *Arch Gynecol Obstet* 275:287-289, 2007.
94. N.K. Gatselis, K. Tepetes, A. Loukopoulos, K. Vasiou, A. Zafiriou, C. Gioti, and **G.N. Dalekos**. Hepatitis B virus and intrahepatic cholangiocarcinoma: report of two cases and review of the literature. *Cancer Investigation* 25:55-8, 2007.
95. E.I. Rigopoulou, D-P Bogdanos, C. Liaskos, A. Koutsoumpas, H. Baum, D. Vergani, **and G.N. Dalekos**. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. *Clin Chim Acta* 380:118-21, 2007.
96. E.I. Rigopoulou, **G. Dalekos**, D.P. Bogdanos. How common are connective tissue disorders in patients with autoimmune hepatitis? *Sem Arthritis Rheum (Letter)* 36:332, 2007.
97. D.P. Bogdanos, C. Liaskos, A. Pares, G. Norman, E.I. Rigopoulou, L. Caballeria, **G.N. Dalekos**, J. Rodes, D. Vergani. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. *Hepatology (Letter)* 45:1583, 2007.

98. S. Gabeta, G.L. Norman, C. Liaskos, P.A. Papamichalis, T. Zografos, A. Garagounis, E.I. Rigopoulou **and G.N. Dalekos**. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. *J Clin Immunol* 27:378-387, 2007.
99. P.A. Papamichalis, K. Zachou, G.K. Koukoulis, A. Veloni, E.G. Karacosta, L. Kypri, I. Mamaloudis, S. Gabeta, E.I. Rigopoulou, A.W. Lohse **and G.N. Dalekos**. The revised international autoimmune hepatitis (AIH) score in chronic liver diseases including AIH/overlap syndromes and AIH with concurrent other liver disorders. *J Autoimmune Dis* 4:3, 2007.
100. E.I. Rigopoulou, E.T. Davies, D.P. Bogdanos, C. Liaskos, G.K. Koukoulis, **G.N. Dalekos**, P. Vergani. Anti-mitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. *Liver Int* 27:1226-1231, 2007.
101. T.A. Zografos, C. Liaskos, E.I. Rigopoulou, E. Togousidis, K. Makaritsis, A. Germenis, **and G.N. Dalekos**. Adiponectin: a new independent predictor of liver steatosis and response to IFN- $\alpha$  treatment in chronic hepatitis C? *Am J Gastroenterol* 103:605-614, 2008.
102. E.I. Rigopoulou **and GN Dalekos**. Autoimmune hepatitis: of host and pathogen. *Hepatology (letter)* 47:2147-2148, 2008.
103. E. M. Hennes, M Zeniya, A. J. Czaja, A. Parés, **G. N. Dalekos**, E. Krawitt, P.L. Bittencourt, G. Porta, K.M. Boberg, H. Hofer, F.B. Bianchi, M Shibata, C. Schramm, B. Eisenmann de Torres, P. R. Galle, I. McFarlane, H. P. Dienes, A. W. Lohse. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 48:169-176, 2008.
104. Y. Renaudineau, **G.N. Dalekos**, P. Guéguen, K. Zachou, P. Youinou. Anti- $\alpha$ -actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. *Clin Rev Allergy Immunol* 34:321-325, 2008.
105. **G.N. Dalekos**, D.P. Bogdanos and J. Neuberger. Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: What is the message? *Liver International* 28:426-428, 2008. **(Editorial)**.
106. K. Zachou, P. Papamichalis, **and G.N. Dalekos**. Severe pharyngitis in stockbreeders: an unusual presentation of brucellosis. *Occup Med* 58:305-307, 2008.
107. E.I. Rigopoulou **and G.N. Dalekos**. Molecular diagnostics of primary biliary cirrhosis. *Expert Opin Med Diagn* 2: 621-634, 2008. **(Invited review)**.
108. D.P. Bogdanos **and G.N. Dalekos**. Enzymes as autoantigens of liver-specific autoimmunity. *Curr Med Chem* 15:2285-2292, 2008. **(Invited review)**.
109. A. Tsirikoni, E.I. Rigopoulou, K. Zachou, C. Liaskos, D. Kyriakou, **and GN Dalekos**. Bone marrow findings in patients with autoimmune liver diseases. *J Gastroenterol Hepatol* 23: e416-21, 2008.
110. K. Kyriakopoulou, A. Antoniou, I.V. Fezoulidis, N.L. Kelekis, **G.N. Dalekos**, M. Vlychou. The role of Doppler Perfusion Index as screening test in the characterization of focal liver lesions. *Digest Liver Dis* 40: 755-60, 2008.
111. N.K. Gatselis, S. Barbanis, F. Karasavidou, **G.N. Dalekos**. Could 90's be a second childhood period? The case of Henoch-Schonlein purpura. *Age & Ageing* 37: 483, 2008.
112. P. Fytily, **G.N. Dalekos**, M. Cornberg, V. Schlaphoff, W. Zauner, K. Zachou, M.P. Manns, C. Klade and H. Wedemeyer. Cross-genotype-reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV. *Vaccine* 26: 3818-26, 2008.

113. Stefanidis I, Giannopoulou M, Liakopoulos V, Dovas S, Karasavvidou F, Zachou K, Koukoulis GK, **Dalekos GN**. A case of membranous nephropathy associated with Sjogren syndrome, polymyositis and autoimmune hepatitis. *Clin Nephrol* 70: 245-50, 2008.
114. S. Gabeta, G.L. Norman, C. Liaskos, N. Gatselis, P.A. Papamichalis, A. Garagounis, K. Zachou, E.I. Rigopoulou **and G.N. Dalekos**. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. *J Clin Immunol* 28: 501-11, 2008.
115. I. Goulis **and G.N. Dalekos**. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. *Expert Rev Anti-Infect Ther* 6:855-859, 2008. **(Invited review)**.
116. A. Stefos, N. Gatselis, K. Zachou, E. Rigopoulou, C. Hadjichristodoulou, **and G.N. Dalekos**. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in central Greece. *Eur J Intern Med* 20: 35-43, 2009.
117. S.P. Georgiadou, C. Liaskos, K. Zachou, S. Gabeta, E.I. Rigopoulou, **and G.N. Dalekos**. Occult hepatitis B virus infection in Greek patients with autoimmune liver diseases. *Liver Int* 29: 434-42, 2009.
118. Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, **Dalekos GN**. Polyclonal hypergammaglobulinaemia and high smooth muscle autoantibodies titres with specificity against filamentous actin: Think about visceral leishmaniasis, not only autoimmune hepatitis. *Int J Infect Dis* 13: e157-60, 2009.
119. S.P. Georgiadou **and G.N. Dalekos**. Which level of immunosuppression is harmful for occult hepatitis B virus infection?: 'A million dollar' answer. *Liver Int* 29: 1127-1128, 2009.
120. KP Makaritsis, Ch Neocleous, N Gatselis, E Petinaki **and GN Dalekos**. An immunocompetent patient presenting with severe septic arthritis due to *Ralstonia pickettii* identified by molecular-based assays: a case report. *Cases J* 2: 8125, 2009.
121. E. Kapsalaki, N. Gatselis, A. Stefos, K. Makaritsis, A. Vassiou, I. Fezoulidis, **G.N. Dalekos**. Spontaneous Spondylodiscitis: Presentation, risk factors, diagnosis, management and outcome *Int J Infect Dis* 13: 564-569, 2009.
122. A. Koutsoumpas, M. Mytilinaiou, D. Polymeros, **G.N. Dalekos**, D.P. Bogdanos. Anti-*Helicobacter pylori* antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific anti-mitochondrial antibodies. *Eur J Gastroenterol Hepatol (letter)* 21: 1220, 2009.
123. E. Tsironi, N. Gatselis, M.G. Kotoula, K. Zachou, M. Pefkianaki, F. Zacharaki, D.Z. Chatzoulis **and G.N. Dalekos**. Ocular disorders as the prevailing manifestations of the antiphospholipid syndrome: three case reports. *Cases J* 2:159, 2009.
124. K. Zachou, C. Yurdaydin, U. Drebber, **G.N. Dalekos**, A. Erhardt, Y Cakaloglu, H. Degertekin, S. Gurel, S. Zeuzem, H. Bozkaya, V. Schlaphoff, H.P. Dienes, C.T. Bock, M.P. Manns and H. Wedemeyer for HDT-1 Study Group. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. *Liver Int* 30:430-437, 2010.
125. P. Mina, S.P. Georgiadou, C. Rizos, **G.N. Dalekos**, E.I. Rigopoulou. Prevalence of occult HBV infection in haemodialysis patients from central Greece. *World J Gastroenterol* 16:225-31, 2010.
126. Liaskos C, Norman GL, Moulas A, Garagounis A, Goulis I, Rigopoulou EI, **Dalekos GN**. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. *Clin Chim Acta* 411:411-5, 2010.
127. E.I. Rigopoulou, **G.N. Dalekos**. Can mathematical models be useful in clinical hepatology? *Liver Int* 30:637-638, 2010. **(Editorial)**.

128. Gatselis NK, Zachou K, **Dalekos GN**. Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. *Gastroenterol Res Pract* 2010. pii: 121620, 2010.
129. Gatselis NK, Zachou K, Papamichalis P, Koukoulis GK, Gabeta S, **Dalekos GN**, Rigopoulou EI. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score? *Digest Liver Dis* 42:807-812, 2010.
130. Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, **Dalekos GN**, Milkiewicz P, Czaja AJ, Heathcote JE, Hirschfield GM, Tan EM, Miyachi K, Bignotto M, Battezzati P-M, Lleo A, Leung PS, Podda M, Gershwin ME, Invernizzi P. PBC Screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. *J Autoimmun* 35:436-442, 2010.
131. Gatselis NK and **Dalekos GN**. Education and imaging. Hepatobiliary and pancreatic: Primary hepatic lymphoma. *J Gastroenterol Hepatol* 26:210, 2011.
132. Gatselis NK, Makaritsis KP, Gabranis I, Karanikas K and **Dalekos GN**. Unusual cardiovascular complications of brucellosis presenting in two men: two case reports and a review of the literature. *J Med Case Reports* 5:22, 2011.
133. Wedemeyer H, Yurdaydin C, **Dalekos GN**, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP. Peginterferon plus adefovir versus either drug alone for hepatitis delta. *New Engl J Med* 364:322-331, 2011.
134. Zachou K, **Dalekos GN**. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. *Liver Int* 31:277-279, 2011. (Editorial).
135. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, **Dalekos GN**. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. *J Hepatol* 55:636-646, 2011.
136. Oikonomou KG, Zachou K, **Dalekos GN**. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. *Autoimmun Rev* 10:389-396, 2011.
137. Papamichalis P, Argyraki K, Papamichalis M, Loukopoulos A, **Dalekos GN**, Rigopoulou EI. Salmonella enteritidis infection complicated by acute myocarditis: a case report and review of the literature. *Cardiol Res Pract* 2011:574230, 2011.
138. Koumati E, Palassopoulou M, Matsouka P, Polyzos A, **Dalekos GN**, Zachou K. Multiple autoimmune propensity and B-non-hodgkin lymphoma: cause or effect? *Autoimmune Dis* 2011:841325, 2011.
139. Argyraki CK, Gabeta S, Zachou K, Boulbou M, Polyzos A, **Dalekos GN**. Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. *Eur J Intern Med* 22:155-157, 2011.
140. Papamichalis P, Alexiou A, Boulbou M, **Dalekos GN**, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? *Clin Res Hepatol Gastroenterol* 36:84-93, 2012.
141. Mederacke I, Yurdaydin C, **Dalekos GN**, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H, Hep-Net/International Delta Hepatitis Study Group. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon- $\alpha$ 2a treatment. *Antivir Ther* 17:305-312, 2012.

142. Tillmann HL, Zachou K, **Dalekos GN**. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? *Liver Int* 32:544-553, 2012.
143. Mavroidi A, Miriagou V, Malli E, Stefos A, **Dalekos GN**, Tzouvelekis LS, Petinaki E. Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2  $\beta$ -lactamase. *Int J Antimicrob Agents* 39:247-250, 2012.
144. Zachou K, Oikonomou K, Renaudineau Y, Chauveau A, Gatselis N, Youinou P, **Dalekos GN**. Anti- $\alpha$  actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. *Aliment Pharmacol Ther* 35:116-125, 2012.
145. Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, **Dalekos GN**, Manns MP, Wedemeyer H; on behalf of Hep-Net/International Delta Hepatitis Study Group. Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. *J Viral Hepat* 19:387-395, 2012.
146. Gatselis NK, Liamis G, Makaritsis KP, **Dalekos GN**. Metabolic acidosis during treatment of mushroom poisoning: a diagnostic pitfall. *Intern Med* 51:1077-1080, 2012.
147. Gatselis NK, Zachou K, Norman GL, Tzellas G, Speletas M, Gabeta S, Germanis A, Koukoulis GK, **Dalekos GN**. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. *Clin Chim Acta* 413:1683-1688, 2012.
148. Stefos A, Gatselis N, Goudelas A, Mpakarosi M, Papaparaskevas J, **Dalekos G**, Petinaki E. Cutaneous infection caused by Bacillus anthracis in Larissa, Thessaly, Central Greece, July 2012. *Euro Surveill* 17(32). pii: 20245, 2012.
149. Zografos TA, Gatselis N, Zachou K, Liaskos C, Gabeta S, Koukoulis GK, **Dalekos GN**. PBC-specific autoantibodies in first degree relatives of Greek PBC patients. *World J Gastroenterol* 18:4721-4728, 2012.
150. Kabaçam G, **Dalekos GN**, Cakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçın K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. *Turk J Gastroenterol* 23:560-568, 2012.
151. Skrimpas S, Polyzos A, **Dalekos GN**, Zachou K. Quiz: Sternoclavicular joint swelling in a previously healthy adult. *Internal Med: Open Access* 2:2, 2012.
152. Saitis A, Gatselis NK, **Dalekos GN**. Leishmaniasis-associated haemophagocytic syndrome revisited: not an uncommon clinical presentation of leishmaniasis. *J Med Cases* 3:315-318, 2012.
153. Mavroidi A, Miriagou V, Liakopoulos A, Tzelepi E, Stefos A, **Dalekos GN**, Petinaki E. Ciprofloxacin-resistant Escherichia coli in Central Greece: mechanisms of resistance and molecular identification. *BMC Infect Dis* 12:371, 2012.
154. Zellos A, Spoulou V, Roma-Giannikou E, Karentzou O, **Dalekos GN**, Theodoridou M. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? *Ann Hepatol* 12:147-151, 2013.
155. Ntaios G, Gatselis NK, Makaritsis K, **Dalekos GN**. Adipokines as mediators of endothelial function and atherosclerosis. *Atherosclerosis* 227:216-221, 2013.
156. J.Z. Liu, J.R. Hov, T. Folseraas, E. Ellinghaus, S.M. Rushbrook, N.T. Doncheva, O.A. Andreassen, R.K. Weersma, T.J. Weismüller, B. Eksteen, P. Invernizzi, G.M. Hirschfield, D.N. Gotthardt, A. Pares, D. Ellinghaus, T. Shah, B.D. Juran, P. Milkiewicz, C. Rust, C. Schramm, T. Müller, B. Srivastava, **G. Dalekos**, M.M. Nöthen, J. Winkelmann, M. Mitrovic, F. Braun,

C.Y. Ponsioen, P.J.P. Croucher, M. Sterneck, A. Teufel, A.L. Mason, J. Saarela, V. Leppa, V. Pelkonen, R. Dorfman, D. Alvaro, A. Floreani, S. Onengut-Gumuscu, S.S. Rich, W.K. Thompson, A.J. Schork, S. Næss, I. Thomsen, G. Mayr, I.R. König, K. Hveem, I. Cleynen, J. Gutierrez-Achury, I. Ricaño-Ponce, D. van Heel, E. Björnsson, R.N. Sandford, P.R. Durie, E. Melum, M.H. Vatn, M. Silverberg, R.H. Duerr, L. Padyukov, S. Brand, M. Sans, V. Annese, Jean-Paul Achkar, K.M. Boberg, H-U Marschall, O. Chazouillères, C.L. Bowlus, C. Wijmenga, E. Schrumpf, S. Vermeire, M. Albrecht, The UK-PSC Consortium, The International IBD Genetics Consortium, J.D. Rioux, G. Alexander, A. Bergquist, J. Cho, S. Schreiber, M.P. Manns, M. Färkkilä, A.M. Dale, R.W. Chapman, K.N. Lazaridis, The International PSC Study Group, A. Franke, C.A. Anderson, T.H. Karlsen. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics* 45:670-675, 2013.

157. Gatselis NK, Ntaios G, Makaritsis K, **Dalekos GN**. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. *Clin Exp Med* 2013 (In press).
158. A Mazioti, NK Gatselis, C Rountas, K Zachou, DK Filippiadis, K Tepetes, GK Koukoulis, I Fezoulidis, **GN Dalekos**. Safety and efficacy of transcatheter arterial chemoembolization in the real-life management of unresectable hepatocellular carcinoma. *Hepat Mon* 2013 (In press).
159. Rigopoulou EI, Zachou K, Gatselis N, Koukoulis GK, **Dalekos GN**. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. *Ann Hepatol* 2013 (In press).
160. Saitis A, Gatselis N, Zachou K, **Dalekos GN**. Use of TNF $\alpha$  antagonists in refractory AIH: revealing the unforeseen. *J Hepatol* 2013 (In press).
161. Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, **Dalekos GN**. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. *Autoimmunity* 2013 (In press).
162. Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, **Dalekos GN**. HBV reactivation in HBsAg negative patients receiving immunosuppression: a hidden threat. *World J Gastrointest Pathophysiol* 2013 (In press).
163. Manesis EK, Vourli G, **Dalekos G**, Vasiliadis T, Manolaki N, Hounta A, Koutsounas S, Vafiadis I, Nikolopoulou G, Giannoulis G, Germanidis G, Papatheodoridis G, Touloumi G. Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study. *J Hepatol* 2013 (In press).
164. Zachou K, Muratori P, Koukoulis GK, Granito A, **Dalekos GN**, Muratori L. Review article: Autoimmune hepatitis – its aetiopathogenesis, clinical features, diagnosis and management. *Aliment Pharmacol Ther* 2013 (In press).

### C. Chapters in Books

1. **G.N. Dalekos**. *Infections of Hepatotropic Viruses in Multitransfused Patients-Therapeutic approaches*. Syllabuses of the Meeting (Sickle Cell Disease and Thalassaemia), University of Ioannina, Medical School, Child Health Department, Ioannina, Greece, October 8-9, 1994, S-15.
2. E.V. Tsianos, **G.N. Dalekos**. *Primary Sclerosing Cholangitis*. In: Postgraduate Courses in Gastroenterology. University Studio Press, Thessaloniki, Greece, 1996, p. 203-212.
3. **G.N. Dalekos**, E.V. Tsianos. *Aetiopathogenesis of Inflammatory Bowel Disease*. In: Proceedings of the XVI Panhellenic Congress in Gastroenterology. Athens, Greece, 1996, p. 65-83.

4. E.V. Tsianos, **G.N. Dalekos**. *The Liver in Autoimmune Rheumatic Diseases*. In: Postgraduate Courses in Hepatology, Volume IV, Athens, Greece, 1996, p. 71-89.
5. **G.N. Dalekos**. *Immunologic Mechanisms in Inflammatory Bowel Disease*. In: Proceedings of the IIIrd Panhellenic Symposium on Inflammatory Bowel Disease. University Studio Press, Thessaloniki, Greece, 1997, p. 34-53.
6. E.V. Tsianos, **G.N. Dalekos**. *The Gastrointestinal Tract and the Liver in Pregnancy*. In: Textbook of Gynecology and Obstetrics by D. Lolis (Ed), G.Parisianos, Athens, Greece, 1998, p. 519-536.
7. **G.N. Dalekos**. *Laboratory Evaluation in the Diagnosis and Differential Diagnosis of Primary Biliary Cirrhosis and Autoimmune Hepatitis*. In: Proceedings of the 6<sup>th</sup> Panhellenic Congress of the Hellenic Association for the Study of the Liver, Thessaloniki, Greece, 1999, p. 124-135.
8. **G.N. Dalekos**. *Nucleoside Analogues in the Treatment of Chronic HBeAg (+) Hepatitis B*. In: Proceedings of the 25<sup>th</sup> Panhellenic Congress of Medicine, Athens, Greece, 1999, p. 57-65.
9. **G.N. Dalekos**. *Famciclovir for the Treatment of Chronic Hepatitis B*. In: Proceedings of the 1<sup>st</sup> Symposium in Hepatitis B, Athens, Greece, 2000, p. 122-128.
10. P. Obermayer-Straub, J. Perheentupa, S. Braun, A. Kayser, A. Barut, S. Loges, A. Harms, **G. Dalekos**, C.P. Strassburg, M.P. Manns. *Hepatic Autoantigens in Patients with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy*. In: Autoantigens and Autoantibodies: Diagnostic Tools and Clues to Understanding Autoimmunity, Conrad K, Humbel R-L, Meurer M, Shoenfeld, Tan EM (Eds.), Pabst Science Publishers, 2000.
11. **G.N. Dalekos**, E. Makri. *Epidemiological, Clinical and Laboratory Characteristics – Diagnostic Criteria of Autoimmune Hepatitis*. In: Proceedings of the Postgraduate Course in Hepatology, Athens, Greece, 2000, p. 68-82.
12. **G.N. Dalekos**. *Current Aspects in Autoimmune Hepatitis*. In: Proceedings of the 7<sup>th</sup> Panhellenic Congress of the Hellenic Association for the Study of the Liver, Athens, Greece, 2001, p. 78-92.
13. **G.N. Dalekos**. *Portal Hypertension: Pathophysiology and Pathogenesis*. In: Postgraduate Courses in Gastroenterology, University Studio Press, Thessaloniki, Greece, 2001, p. 46-55.
14. **G.N. Dalekos**, C. Liaskos, K. Zachou, E. Makri, M. Venizelos. *Management of asymptomatic patients with elevated liver function tests*. Hellenic Center for the Control of Infectious Diseases, Hellenic Ministry of Health, 2001.
15. **G.N. Dalekos**. *Autoimmune hepatitis: Pathogenesis, Diagnosis, clinical manifestations and treatment*. In: Postgraduate Courses in Pathology, Volcano press, Athens, 2001, p. 42-49.
16. **G.N. Dalekos**. *Cytokines in Inflammatory Bowel Disease*. In: Inflammatory Bowel Disease: The Greek Experience, edited by the Heraklion (Creta) Medical School, Heraklion, Greece, 2001, p.87-100.
17. **G.N. Dalekos**. *Liver and lung*. In: Proceedings of the Postgraduate Course in Hepatology, University Studio Press, Thessaloniki, Greece, 2001, p. 24-39.
18. **G.N. Dalekos**, G. Papadamou. *Treatment of chronic hepatitis C*. In: Proceedings of the Postgraduate Course in Hepatology, University Studio Press, Athens, 2002, p. 133-146.
19. **G.N. Dalekos**. *Autoantibodies in the diagnosis of the diseases of the gastrointestinal tract and the liver*. In: Proceedings of the 28<sup>th</sup> Panhellenic Congress of Medicine, Athens, Greece, 2002, p. 1-14.
20. **G.N. Dalekos**. *Cytokines in Medicine: From Bench to Bedside*. In: Postgraduate Courses in Surgery. Athens, Greece, 2002, p. 35-51.

21. **G.N. Dalekos.** *Decision Making in the Treatment of Difficult Cases of Chronic Hepatitis C Virus Infection.* In: Proceedings of the 8th Symposium on Hepatitis C, by S.I. Hatzilyannis (Ed), P.C. Paschalidis, Athens, Greece, 2003, p. 365-382.
22. **G.N. Dalekos.** *Autoantibodies in diseases of the liver and the alimentary tract.* In: Diagnostic Immunology edited by A.E. Germeis, Larissa, Greece, 2002, p. 1-13.
23. **G.N. Dalekos.** *Hepatitis B and C in Greece: an update from the Hellenic Center for Disease Control and Prevention.* In: Proceedings of the 9th Symposium on Hepatitis C, by S.I. Hatzilyannis (Ed), P.C. Paschalidis, Athens, Greece, 2004, p. 18-26.
24. **G.N. Dalekos.** *Contribution of molecular virology in diagnosis and treatment of viral hepatitis.* In: Proceedings of the Symposium of the Hellenic Association for the Study of the Liver on Viral Hepatitis, Nicosia, Cyprus, Syllabuses of the Meeting, May 7-8, 2004, p. 18-24.
25. **G.N. Dalekos.** *The utility of molecular virology in the clinical management of chronic hepatitis C.* In: Proceedings of the 24<sup>th</sup> Panhellenic Congress of Gastroenterology, November 6-9, 2004, p.23-27.
26. G. Kitis, E. Manesis, M. Deutsch, B. Papadimitropoulos, S. Savas, G. Germanidis, J. Goulis, and **G.N. Dalekos.** *Decision making in hepatitis C.* In: Proceedings of the 9th Symposium on Hepatitis B and C, by S.I. Hatzilyannis (Ed), ALFAPAK Ltd, Athens, 2005, p. 129-138.
27. **G.N. Dalekos.** *Autoimmune hepatitis: Impact of symptoms and cirrhosis on the natural history and outcome of the disease.* In: News in Rheumatology, October/November/December 2005, p. 29-30.
28. **G.N. Dalekos.** *Autoimmune liver diseases: Differential diagnosis and treatment.* In: Proceedings of the Educational Seminar of the Hellenic Association of Research and Education in Primary Care, Plastira lake, Karditsa, 2005, p. 85-102.
29. **G.N. Dalekos.** *Autoimmune liver diseases.* In: Proceedings of the 20<sup>th</sup> Postgraduate course of the Hellenic Association of Immunology, Athens, October 13-15, 2005, p.13-27.
30. E.Petinaki and **G.N. Dalekos.** *Molecular methods as tools for the diagnosis of bacterial infections: useful or useless?* In: R.M. Mohan (Ed). *Research Advances in Microbiology*, Global Research Network, 2006, p. 23-31.
31. **G.N. Dalekos.** «*Hereditary and Metabolic Diseases of the Liver*». Chapter 154, Cecil, Internal Medicine, 18<sup>n</sup> Greek edition, Mendor Editions, Athens, 2010, p. 1122-1128.
32. **G.N. Dalekos.** «*Bacterial, Parasitic, Fungal and Granulomatous Diseases of the Liver*». Chapter 155, Cecil, Internal Medicine, 18<sup>n</sup> Greek edition, Mendor Editions, Athens, 2010, p. 1128-1135.
33. **G.N. Dalekos.** «*Alcoholic and non-Alcoholic Steatohepatitis*». Chapter 156, Cecil, Internal Medicine, 18<sup>n</sup> Greek edition, Mendor Editions, Athens, 2010, p. 1135-1139.
34. **G.N. Dalekos.** «*Diseases of the Gall Bladder and Biliary Tract*». Chapter 159, Cecil, Internal Medicine, 18<sup>n</sup> Greek edition, Mendor Editions, Athens, 2010, p. 1152-1161.
35. E.Petinaki and **G.N. Dalekos.** *Cardiobacterium.* In: Dongyou Liu (Ed). *Molecular detection of human bacterial pathogens*, Taylor & Francis CRC Press, Chapter 70, 2011, p.811-814.
36. **G.N. Dalekos.** *Liver and autoimmunity.* In: Proceedings of the 22<sup>th</sup> Year of Internal Medicine Days, Third Department of Internal Medicine of the Medical School of the University of Athens, Athens, April 5-6, 2013, chapter of invited speakers on CD (7 pages).

37. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Clinical practice guidelines for the management of hepatitis B and hepatitis C infections*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, 2013.

#### D. Papers in Greek Medical Journals

1. **G.N. Dalekos**, P. Aggelis, K. Papadopoulos, D. Perakis. Fatal acute renal failure due to acute rhabdomyolysis in an heroin addict. *Psychiatry Letters* 24: 108-111, 1988.
2. **G.N. Dalekos**, K. Papadopoulos. Heatstroke: Current aspects of its pathophysiology, complications, treatment and prevention. *Iatriki* 56: 426-436, 1989.
3. **G.N. Dalekos**, P. Aggelis, D. Christodoulou, K. Katsikis. Dermatomyositis as first manifestation of pancreatic cancer. *Iatriki* 57: 74-77, 1990.
4. **G.N. Dalekos**, D. Kairis, E. Drimilis. Concentrations of magnesium in the sera of patients with delirium tremens due to alcohol withdrawal. *Psychiatry Letters* 33: 144-148, 1991.
5. **G.N. Dalekos**. Prostaglandins: Their role in cytoprotection and in cirrhosis of the liver. *Iatriki* 60: 231-242, 1991.
6. **G.N. Dalekos**, D. Kairis, P. Aggelis, K. Papadopoulos. Concentrations of selenium in the sera of patients with delirium tremens due to alcohol withdrawal. *Arch Hell Med* 8: 120-123, 1991.
7. **G.N. Dalekos**, C.N. Masalas, M. Merkouropoulos, E.V. Tsianos. Epidemiology of ulcerative colitis in the area of Epirus, Greece. *Hell J Gastroenterol* 4: 283-288, 1991.
8. K. Masalas, **G.N. Dalekos**, M. Merkouropoulos, E.V. Tsianos. The constipation as a presenting symptom at the first attack of ulcerative colitis. *Arch Hell Med* 9: 201-204, 1992.
9. **G.N. Dalekos**, M. Merkouropoulos, A. Mavridis, E. Zervou, K. Masalas, E.V. Tsianos. Frequency of hepatitis C in heroin addicts. *Iatriki* 63: 51-54, 1993.
10. **G.N. Dalekos**, E.V. Tsianos. Hepato-pulmonary syndrome: Is this a functional lung failure in liver cirrhosis? *Iatriki* 63: 449-458, 1993.
11. **G.N. Dalekos**, M. Stamouli, P. Aggelis. The glycosylated haemoglobin A<sub>1</sub> (HbA<sub>1</sub>) in chronic heroin addicts during the withdrawal stage. *Psychiatry Letters* 42: 140-142, 1993.
12. **G.N. Dalekos**, M.N. Manoussakis, M.C. Merkouropoulos. E.V. Tsianos. Autoimmunity and cellular immune activation before and after  $\alpha$ -interferon administration in Greek patients with chronic viral hepatitis. A preliminary study. *Hell J Gastroenterol* 6: 166-171, 1993.
13. **G.N. Dalekos**, M. Stamouli, E. Drimilis, G. Solias. Heroin as a cause of high mean cell volume. *Iatriki* 64: 637-640, 1993.
14. **G.N. Dalekos**, G.C. Liapi, P. Dallas, D. Stefanou, M. Elisaf. Hepatic dysfunction as first manifestation of renal cell carcinoma. A case report and review of the literature. *Hell J Gastroenterol* 6: 267-271, 1993.
15. L. Christou, **G.N. Dalekos**, E.V. Tsianos, K. Bourantas. Brucellosis and ascites. *Iatriki* 67: 77-79, 1995.
16. **G.N. Dalekos**, D.I. Anastasopoulos, M.H. Merkouropoulos, E.V. Tsianos. Choreic movements as neurologic manifestation of ulcerative colitis. Reality or coincidence? *Hell J Gastroenterol* 8: 75-77, 1995.
17. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, N. Papagalani, K.C. Siamopoulos. Interleukin-1 $\beta$  in the systemic circulation of patients with familial hypercholesterolemia and essential hypertension:

Additional risk factor for atherogenesis in hypertensive patients? *Arterial Hypertension* 4: 53-62, 1995.

18. **G.N. Dalekos**, E. Zervou, F. Karabini, H. Liapis, K. Ziciadis, E.V. Tsianos. Frequency of chronic hepatitis C virus (HCV) infection among individuals with indeterminate results after RIBA-II HCV test: A prospective study. Proceedings of the Second Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, P. Paschalides (Pub.), 1995, p. 175-179.
19. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. IgM antibodies to HCV in chronic active hepatitis C in north-western Greece. Solution or more questions? Proceedings of the Second Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, P. Paschalides (Pub.), 1995, p. 180-183.
20. **G.N. Dalekos**, E.V. Tsianos. High concentrations of soluble interleukin-2 receptors and interleukin-6 in active ulcerative colitis. *Hell J Gastroenterol* 8: 319-327, 1995.
21. **G.N. Dalekos**, A. Vlachopoulos, E.V. Tsianos. The epidemiology of inflammatory bowel disease in Ioannina. *Iatriki* 69: 66-74, 1996.
22. **G.N. Dalekos**, E.V. Tsianos. Cytokines in inflammatory bowel disease. *Hell J Gastroenterol (Letter)*, 9: 75-76, 1996.
23. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. Prevalence of anti-HCV antibodies in healthy individuals, chronic alcoholics and refugees from Albania in Epirus region-Greece Proceedings of the Third Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, Paschalides, 1996, p. 157-163.
24. **G.N. Dalekos**, E. Zervou, D.S. Boumba, A. Gerolymatou, E.V. Tsianos. Frequency of viraemia due to hepatitis C virus (HCV) among individuals with indeterminate results after RIBA-II HCV test: A preliminary study. *Hell J Gastroenterol* 9: 160-166, 1996.
25. E. Ioachim, **G.N. Dalekos**, E.V. Tsianos, E. Demou, A.C. Goussia, N.J. Agnantis. Aberrant HLA-DR expression and lymphocyte subsets in inflammatory bowel disease: an immunohistological study on frozen and paraffin sections. *Hell J Gastroenterol* 9: 332-338, 1996.
26. E.V. Tsianos, **G.N. Dalekos**. Inflammatory bowel disease (I). Genetic factors and inflammatory mediators. *Iatriki* 71: 25-30, 1997.
27. **G.N. Dalekos**, E.V. Tsianos. Inflammatory bowel disease (II). Immunologic factors. *Iatriki* 71: 134-142, 1997.
28. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, N. Papagalanis, O.Tsolas, K.C. Siamopoulos. Interleukin-1 $\beta$  and essential hypertension. *Iatriki* 71: 573-580, 1997.
29. **G.N. Dalekos**, D. Boumba, E. Zervou, D. Christodoulou, K. Kistis, E.V. Tsianos. Equivalence (correlation) and clinical significance of serotypes and genotypes of hepatitis C virus: A preliminary study. Proceedings of the Fourth Symposium on Hepatitis C, by S.I. Hatziyannis (Ed), PRESS CONCEPT N. Heraklion, Athens, 1997, p. 183-188.
30. **G.N. Dalekos**, D. Christodoulou, K.G. Kistis, A. Gerolymatou, E.V. Tsianos. The role of interleukin-7 in the induction of the inflammatory cascade in ulcerative colitis patients. More questions than evidence. *Hell J Gastroenterol* 10: 51-53, 1997.
31. E. Zervou, **G.N. Dalekos**, D. Christodoulou, E.V. Tsianos. Prevalence of HCV serotype in Epirus by using an enzyme immunoassay. *Acta Microbiologica Hellenica* 42: 206-209, 1997.
32. E. Zervou, **G.N. Dalekos**, S. Alfantaki, E. Galanakis, P. Lapatsanis, E.V. Tsianos. Prevalence of anti-HAV IgG antibodies in pediatric population and blood donors in N.W. Greece. *Acta Microbiologica Hellenica* 42: 218-222, 1997.

33. **G.N. Dalekos**, E. Zervou, M. Elisaf, D.S. Boumba, K. Katopodis, G. Sferopoulos, K.C. Siamopoulos, E.V. Tsianos. Increased frequency of HGV-RNA detection in hemodialysis patients negative for other blood-borne viruses. *Hell J Gastroenterol* 10: 203-209, 1997.
34. E. Zervou, **G.N. Dalekos**, D. Christodoulou, A. Gerodemou, E.V. Tsianos. Correlation between anti-HBc positivity and HBV viraemia. *Iatriki*,74: 400-403, 1998
35. E. Zervou, **G.N. Dalekos**, A. Gerolymatou, D. Boumba, E.V. Tsianos. Prevalence of hepatitis B and C markers in blood donors in Epirus. *Acta Microbiologica Hellenica* 43: 482-489, 1998
36. **G.N Dalekos**. Molecularly defined target-autoantigens as tools for the diagnosis, differential diagnosis and the study of aetiopathogenesis of autoimmune liver diseases. *Iatriki* 75: 408-418, 1999.
37. Ch. Liaskos, **G.N. Dalekos**. New concepts on the epidemiology and the clinical and laboratory markers for the diagnosis and differential diagnosis of autoimmune hepatitis. *Iatriki* 78: 233-243, 2000.
38. E.Zervou, P. Georgitsi, M. Tzoufi, G.N. Dalekos, M. Pontikaki, K. Zisiadis, E.V. tsianos. Prevalence and clinical characteristics of HGV infection in blood donors and patients with thalassemia major. *Acta Microbiologica Hellenica* 46: 167-171, 2001.
39. K. Zachou, Ch. Liaskos, E. Makri, G. Papadamou, M. Kardasi, A. Pliaka, F. gerovasilis, **G.N. Dalekos**. Anticardiolipin antibodies (a-CLAbs) are not b2-GPI-dependent (non-thrombogenic a-CLAbs): preliminary results in 107 HCV patients from central Greece. In: Proceedings of the 1<sup>st</sup> Symposium on Hepatitis B and C 2001-02, by S.I. Hatziyannis (Ed), Medical press P.C. Paschalidis, Athens, 2003, p. 392-402.
40. S. Georgiadou, K. Zachou, Ch. Liaskos, N. Gatselis, A. Tsikrikoni, F. Gerovasilis, M. Kardasi, E. Makri, G. Papadamou and **G.N. Dalekos**. Increased prevalence of occult hepatitis B virus infection in patients with chronic hepatitis C: absence of association with more severe liver disease. In: Proceedings of the 2<sup>nd</sup> Symposium on Hepatitis B and C 2003, by S.I. Hatziyannis (Ed), Medical press P.C. Paschalidis, Athens, 2004, σ. 304-315.
41. **G.N. Dalekos**. Autoantibodies and autoantigens associated with autoimmune hepatitis and viruses-induced autoimmune response: significant tools in clinical practice and in the study of pathogenesis of autoimmune hepatic diseases. *Archives of Hellenic Medicine* 21:502-527, 2004
42. E.I. Rigopoulou **and G.N . Dalekos**. Current treatment of HBV and HCV infections. *Drugs & Prescription* 11:16-24, 2005.
43. M. Speletas, F. Kalala, **G. Dalekos**. Continuing medical education. Clinical Immunology quiz-Case 1. *Archives of Hellenic Medicine* 24:398, 2007.
44. **G. Dalekos**. Autoimmune liver diseases: Aetiopathogenesis and diagnosis. *Anosia* 8:59-65, 2012.

## E. Citation Index

**3168 citations up to May 2013** (ISI and/or Scopus; self-citations: 136), **h-index = 29**.

## Note

1. I have also presented 193 abstracts in Greek and 140 abstracts in International Congresses.

2. I have acted as chairperson, moderator and speaker in several local (Greek) Congresses, International meetings like EASL and International Immunology Congresses (n=247 in total).